Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 17Carcinoma, Hepatocellular 5Neoplasms 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Liver Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uveal Melanoma 2Stomach Neoplasms 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasm Metastasis 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Basal Cell 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1

Interventions

pembrolizumab 8Nivolumab 6Ipilimumab 3toripalimab 2atezolizumab 2Specimen Handling 2Celecoxib 2relatlimab 1fludarabine phosphate 1fludarabine 1durvalumab 1denileukin diftitox 1camrelizumab 1avelumab 1XELOX 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Irinotecan 1Interleukin-2 1Induction Chemotherapy 1Immunotherapy 1Immune Checkpoint Inhibitors 1IMM-101 1E7777 fusion protein 1Docetaxel 1Diffusion Tensor Imaging 1DNA Mismatch Repair 1DEAE-Dextran 1Cyclophosphamide 1Colonoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Turcot syndrome × relatlimab × 1 year × Clear all
NCT03607890 2026-03-16

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
38 enrolled

Turcot syndrome, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡